Journal Scans
A Randomized Trial of a Single-Dose Rasburicase Versus Five-Daily Doses in Patients at Risk for Tumor Lysis Syndrome
Single-Dose Rasburicase May Prevent Tumor Lysis Syndrome
S Vadhan-Raj, LE Fayad, MA Fanale, B Pro, A Rodriguez, FB Hagemeister, CE Bueso-Ramos, X Zhou, PW McLaughlin, N Fowler, J Shah, RZ Orlowski, F Samaniego, M Wang, JE Cortes, A Younes, LW Kwak, NJ Sarlis, JE Romaguera
20110919
2011 Oct 19
Ann Oncol
A Randomized Trial of a Single-Dose Rasburicase Versus Five-Daily Doses in Patients at Risk for Tumor Lysis Syndrome
Ann Oncol. 2011 Oct 19;[Epub Ahead of Print], S Vadhan-Raj, LE Fayad, MA Fanale, B Pro, A Rodriguez, FB Hagemeister, CE Bueso-Ramos, X Zhou, PW McLaughlin, N Fowler, J Shah, RZ Orlowski, F Samaniego, M Wang, JE Cortes, A Younes, LW Kwak, NJ Sarlis, JE Romaguera
TAKE-HOME MESSAGE
Abstract
SUMMARY
OncologySTAT Editorial Team
Tumor lysis syndrome (TLS), which results from massive lysis of malignant cells, is a potential life-threatening complication of treatment. The release of intracellular metabolites from lysed tumor cells can lead to acute renal failure, cardiac arrhythmias, seizures, and death. Rapid catabolism of purine-containing nucleic acids from lysed tumor cells can lead to renal insufficiency caused by precipitation of uric acid (UA) in the kidney. Rasburicase reduces UA levels by catalyzing the conversion...
